Citations

Showing 10 of 107964 citations.

The impact of MMX mesalazine on disease‐specific health‐related quality of life in ulcerative colitis patients
Solomon, Dory, Yarlas, Aaron , Hodgkins, P. , Karlstadt, Robyn G., Yen, L., Kane, Sunanda V.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | April 27, 2012 | Volume: 35 | Issue: 12 | Pages: 1386-1396

10.1111/j.1365-2036.2012.05107.x | PMID 22536781 Get It

SummaryBackgroundPast studies with ulcerative colitis (UC) patients indicate that disease activity strongly predicts health‐related quality of life (HRQL).AimTo examine the degree to which daily treatment with MMX mesalazine predicts improved HRQL for patients with active UC and with stable HRQL for patients with quiescent UC.MethodsData from two phases of a multicentre open‐label trial were examined. In the acute phase, 132 patients with mild‐to‐moderate active UC received MMX mesalazine 2.4–4.8 g/day for 8 weeks, while 206 patients with quiescent UC received MMX mesalazine 2.4 g/day for a 12‐month maintenance phase. Disease‐specific HRQL was measured at baseline and endpoint of each phase using the Short Inflammatory Bowel Disease Questionnaire (SIBDQ). Repeated‐measures anova models examined baseline‐endpoint changes in SIBDQ, stool frequency (SF), and rectal bleeding severity (RBS). Correlations assessed the associations between SIBDQ and SF/RBS scores, while ancova techniques tested the sensitivity of SIBDQ to disease recurrence.ResultsSIBDQ scores significantly increased for active mild‐to‐moderate UC patients following 8 weeks of treatment, while SIBDQ scores remained stable for quiescent UC patients following 12 months of treatment. Changes in SIBDQ scores correlated significantly with changes in SF and RBS scores. Patients with recurrent UC at maintenance phase endpoint had significantly lower SIBDQ scores than nonrecurrent patients.ConclusionsDaily MMX mesalazine therapy was associated with significant improvement in disease‐specific HRQL for patients with mild‐to‐moderate active UC and with the maintenance of HRQL for patients with quiescent UC. In both patient groups, HRQL was significantly associated with disease activity.
Prognostic irrelevance of ring sideroblast percentage in World Health Organization–defined myelodysplastic syndromes without excess blasts
Patnaik, Mrinal M. , Hanson, Curtis A. , Sulai, Nanna, Hodnefield, Janice M., Knudson, Ryan A., Ketterling, Rhett P. , Tefferi, Ayalew , Lasho, Terra L. , Ketterling, Rhett P

Mayo Clinic

Blood | April 27, 2012 | Volume: 119 | Issue: 24 | Pages: 5674-5677

10.1182/blood-2012-03-415356 | PMID 22538853 Get It

Abstract The presence of ≥ 15% bone marrow (BM) ring sideroblasts (RS) and < 5% blasts is required for a diagnosis of refractory anemia with ring sideroblasts. We examined the phenotypic and prognostic relevance of this “15%” RS threshold in 200 patients with myelodysplastic syndromes (MDS) without excess blasts and with ≥ 1% RS. The impact of RS% was assessed both as a continuous and categorical variable: < 5% (n = 56), 5%-14% (n = 32), 15%-50% (n = 79), and > 50% (n = 33). RS% correlated (P < .05) directly with age, platelet count, transfusion dependency, BM cellularity, and mutant SF3B1 and inversely with hemoglobin level, multilineage dysplasia, and high-risk karyotype; but did not correlate with IDH mutations. At a median follow-up of 33 months, 156 (73%) deaths and 24 (12%) leukemic transformations were documented. Neither univariate nor multivariable analysis showed significant effect for RS% on overall or leukemia-free survival, suggesting the limited prognostic value of quantifying BM RS in MDS.
Letter by Freeman and Taussky Regarding Article, “Near Infrared Spectroscopy for the Detection of Desaturations in Vulnerable Ischemic Brain Tissue: A Pilot Study at the Stroke Unit Bedside”
Freeman, William D. , Taussky, Philipp , Freeman, William D

Mayo Clinic

Stroke | April 27, 2012 | Volume: 43 | Issue: 7 | Pages: No page available

10.1161/strokeaha.112.652792 | PMID 22539547 Get It

Chronic constipation: new diagnostic and treatment approaches
Lacy, Brian E. , Levenick, John M. , Crowell, Michael D. , Crowell, Michael D

Mayo Clinic

Therapeutic Advances in Gastroenterology | April 27, 2012 | Volume: 5 | Issue: 4 | Pages: 233-247

10.1177/1756283x12443093 | PMID 22778789 Get It

Chronic constipation is a highly prevalent disorder that affects approximately 15% of the US population. Chronic constipation refers to patients who have had symptoms for more than 6 months. In clinical practice, chronic constipation is often used interchangeably with the term functional constipation. This is best defined using the Rome III criteria, which involves an evaluation of stool frequency in addition to symptoms of straining, feelings of incomplete evacuation, and the need to use manual maneuvers to assist with stool evacuation. Symptoms can be burdensome, leading to a reduction in patients’ quality of life. As a national healthcare issue, chronic constipation is also important because it imposes a significant economic impact on the healthcare system. A number of treatment options are currently available, both over-the-counter and by prescription, although not all patients respond to these therapies. This review will focus on new medical treatment options for the management of chronic constipation, and the safety and efficacy of these agents will be reviewed. In addition, the efficacy of new diagnostic tests to evaluate colonic motility and anorectal function are described.
Emerging synaptic biomarkers in autoimmune dementia
Pittock, Sean J. , Balice‐Gordon, Rita J. , Pittock, S J

Mayo Clinic

Neurology | April 27, 2012 | Volume: 78 | Issue: 22 | Pages: 1710-1711

10.1212/wnl.0b013e31825830f3 | PMID 22539567 Get It

Genotype patterns atPICALM, CR1, BIN1, CLU, andAPOEgenes are associated with episodic memory
Barral, Sandra , Bird, Thomas D., Goate, Alison , Farlow, MR, Diaz‐Arrastia, Ramon , Bennett, David A. , Graff-Radford, N. R., Stern, Yaakov , Ott, Jürg , Mayeux, Richard , Kowall, Neil W. , Williamson, Jennifer, Santana, Vincent, Schmechel, Donald E., Gaskel, Peter, Farlow, Martin R. , Faber, Kelley, Horner, Kelly, Growdon, John H., Blacker, Deborah , Tanzi, Rudolph E. , Kuntz, Karen M. , Norgaard, Lindsay, Larson, Nathan, Kistler, Dana, Parfitt, Francine, Haddow, Jenny, Silverman, Jeremy M. , Beeri, Michal Schnaider , Sano, Mary , Wang, Joy , Lally, Rachel, Johnson, Nancy, Mesulam, Marcel, Weıntraub, Sandra , Bigio, Eileen H. , Kaye, Jeffery, Kramer, Patricia, Payne-Murphy, Jessica, Jacobs, Holli, Chang, Joon, Arends, Danielle, Harrell, Lindy, Bartzokis, George, Cummings, Jeffery L., Lu, Po H. , Toland, Usha, Smith, Charles , Brickhouse, Alise, Trojanowski, John Q. , DeKosky, Steven T. , Weamer, Elise A., Chui, Helena C., Varpetian, Arousiak, Rosenberg, Roger N., Schellenberg, Gerard D. , Raskind, Murray A. , Rumbaugh, Malia, Nickel, Kate, Norton, Joanne, Levitch, Denise, Grant, B., Coats, Mary A., Levey, Allen, Rosen, Ami, Anosike, Ezinna, Bennett, David A. , Wilson, Robert S. , Boeve, Bradley F. , Sweet, Robert A. , Wilson, R. J. , Foroud, Tatiana , Green, Robert C. , Farrer, Lindsay A. , Ghetti, Bernardino , Prentice, Heather A. , Hyman, Bradley T. , Larson, Nathan, Kaye, Jeffery, Deerlin, Vivianna M. Van , Wood, Elisabeth McCarty , Davis, Barbara Allen , Morris, John A. , Stern, Yaakov , Goate, Alison M , Diaz-Arrastia, Ramon

Mayo Clinic

Neurology | April 27, 2012 | Volume: 78 | Issue: 19 | Pages: 1464-1471

10.1212/wnl.0b013e3182553c48 | PMID 22539578 Get It

An Unusual Foreign Body in the Urinary Bladder Mimicking a Parasitic Worm
Schmitt, Bryan H., Feder, Marc, Rokke, Denise L., Moyer, Thomas P. , Pritt, Bobbi S. , Rokke, Denise, Pritt, Bobbi S

Mayo Clinic

Journal of Clinical Microbiology | April 27, 2012 | Volume: 50 | Issue: 7 | Pages: 2520-2522

10.1128/jcm.00532-12 | PMID 22535991 Get It

ABSTRACTWe report an unusual case of a foreign body removed from the urinary bladder of a 63-year-old male which mimicked a parasitic worm. The foreign body was identified as an artificial fishing worm by morphological comparison to a similar commercially produced product and by infrared spectrum analysis.
“Malignant” Perivascular Epithelioid Cell Neoplasm: Risk Stratification and Treatment Strategies
Bleeker, Jonathan , Quevedo, J. Fernando , Folpe, Andrew L.

Mayo Clinic

Sarcoma | April 26, 2012 | Volume: 2012 | Issue: No issue available | Pages: 1-12

10.1155/2012/541626 | PMID 22619565 Get It

Purpose . Perivascular epithelioid cell tumors (PEComas) are a rare collection of tumors characterized by a myomelanocytic phenotype, and PEComas occurring in “nonclassic” anatomic distributions are known as perivascular epithelioid cell tumor not otherwise specified (PEComa-NOS). This review aims to compile and analyze cases of PEComa-NOS in an effort to better define their natural history. Design . We evaluated all 234 cases of PEComa-NOS reported in the English literature, extracting information regarding diagnostic features, treatment approaches, and outcomes. Multivariate analysis of a number of variables evaluable on pathologic review was performed to refine preexisting risk stratification criteria. Outcomes for patients receiving nonsurgical treatment are also reported. Results . Primary tumor size ≥5 cm ( P = 0.02 ) and a high (1/50 HPF) mitotic rate ( P < 0.0001 ) were the only factors significantly associated with recurrence following surgical resection. Cytotoxic chemotherapy and radiation therapy have shown little benefit in treating PEComa-NOS; mTOR inhibition is emerging as a treatment option. Conclusion . Progress has been made in understanding the natural history and molecular biology of PEComa-NOS. This review further clarifies risk of recurrence in this disease, allowing clinicians to better risk stratify patients. Further work should focus on applying this knowledge to making treatment decisions for patients with this disease.
Clinical presentation and prognostic factors of spinal dural arteriovenous fistulas: an overview
Fugate, Jennifer E. , Lanzino, Giuseppe , Rabinstein, Alejandro A.

Mayo Clinic

Neurosurgical Focus | April 26, 2012 | Volume: 32 | Issue: 5 | Pages: E17

10.3171/2012.1.focus11376 | PMID 22537126 Get It

Spinal dural arteriovenous fistulas (AVFs), the most common type of spinal cord vascular malformation, can be a challenge to diagnose and treat promptly. The disorder is rare, and the presenting clinical symptoms and signs are nonspecific and insidious at onset. Spinal dural AVFs preferentially affect middle-aged men, and patients most commonly present with gait abnormality or lower-extremity weakness and sensory disturbances. Symptoms gradually progress or decline in a stepwise manner and are commonly associated with pain and sphincter disturbances. Surgical or endovascular disconnection of the fistula has a high success rate with a low rate of morbidity. Motor symptoms are most likely to improve after treatment, followed by sensory disturbances, and lastly sphincter disturbances. Patients with severe neurological deficits at presentation tend to have worse posttreatment functional outcomes than those with mild or moderate pretreatment disability. However, improvement or stabilization of symptoms is seen in the vast majority of treated patients, and thus treatment is justified even in patients with substantial neurological deficits. The extent of intramedullary spinal cord T2 signal abnormality does not correlate with outcomes and should not be used as a prognostic factor.
Curative Onyx embolization of tentorial dural arteriovenous fistulas
Puffer, Ross C. , Kallmes, David F. , Cloft, Harry J. , Daniels, David J. , Lanzino, Giuseppe

Mayo Clinic

Neurosurgical Focus | April 26, 2012 | Volume: 32 | Issue: 5 | Pages: E4

10.3171/2011.12.focus11323 | PMID 22537130 Get It

Object The authors conducted a study to review their experience with tentorial dural arteriovenous fistulas (DAVFs) treated with transarterial endovascular embolization in which Onyx was used. Methods The authors reviewed prospectively collected data in 9 patients with tentorial DAVFs treated with Onyx embolization between 2008 and 2011. Information reviewed included clinical presentation, angiographic features, treatment, and clinical and radiologically documented outcome. Clinical follow-up was available in every patient. Radiological follow-up studies were available in 8 of 9 patients (mean follow-up 4.6 months). Results Six of 9 patients had complete angiographic obliteration (in 5 this was confirmed by a follow-up angiogram obtained 3–6 months later), and 2 patients had near-complete obliteration (faint filling of the venous drainage in the late venous phase). One patient had partial obliteration and required surgical disconnection. In all patients with complete obliteration, transarterial embolization was performed through the posterior branch of the middle meningeal artery. There were no procedural complications, and no morbidity or mortality resulted from Onyx embolization. Conclusions Transarterial Onyx embolization is a valid, effective, and safe alternative to surgical disconnection in many patients with tentorial DAVFs. The presence of an adequate posterior branch of the middle meningeal artery is critical to achieve a microcatheter position distal enough to increase the likelihood of complete obliteration.